Yang (2020)
Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patients.
10.18632/aging.102999
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185104/
Treatment
Treatment for COVID-19 (Treated with Thymosin therapy vs. Not received)
COVID-19 (severe/critical)
Risk ratio: 2.320 (0.940-5.730) Adjusted model

China

Prospective cohort study

Medical records

273

273 diagnosed COVID-19 patients with mild category in Shanghai Public Health Clinical Center were included in this analysis.

The average age of 273 COVID-19 patients enrolled with imaging progression were older than those without imaging progression (p = 0.006). The optimal cutoff of age for predicting imaging progression on chest CT was 51 years.

Total

7 Day


COVID-19 (severe/critical)

71

71 COVID-19 patients suffered from imaging progression on chest CT at first week after admission, and the other 202 patients were imaging progression-free on chest CT.


Treatment

Treatment for COVID-19

none

Not received

Treated with Thymosin therapy


Risk ratio

2.320 (0.940-5.730)

No

No

Yes

Age, gamma globulin therapy, thymosin therapy, Monocyte-lymphocyte ratio (MLR), serum cystatin C, homocysteine, estimated glomerular filtration rate (eGFR) and period from onset to admission.


Age, MLR, homocysteine and period from onset to admission could predict imaging progression on chest CT from COVID-19

Good

Yes